Roginolisib - iOnctura
Alternative Names: IOA-244Latest Information Update: 05 Sep 2024
Price :
$50 *
At a glance
- Originator Cancer Research Technology; Merck & Co
- Developer iOnctura
- Class Antineoplastics; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Uveal melanoma
- Phase II Chronic lymphocytic leukaemia; Myelofibrosis; Non-small cell lung cancer; Peripheral T-cell lymphoma
- Phase I/II Haematological malignancies; Solid tumours
- Phase I Malignant melanoma; Mesothelioma; Non-Hodgkin's lymphoma
Most Recent Events
- 05 Sep 2024 Phase-II clinical trials in Chronic lymphocytic leukaemia (unspecified route) (iOnctura pipeline, September 2024)
- 05 Sep 2024 Phase-II clinical trials in Myelofibrosis (PO) (iOctura pipeline, September 2024).
- 05 Sep 2024 Phase-II clinical trials in Non-small cell lung cancer (PO) (iOctura pipeline, September 2024).